Abstract:Ligustilide (LIG) is the main active ingredient of Angelica sinensis (Oliv.) Diels and has a neuroprotective effect against ischemic stroke. However, owing to its multi-conjugated unstable structure, the compound has poor drug-forming properties. Therefore, we synthesized highly stable colorless needle crystals (known as ligusticum cycloprolactam, LIGc) through the structural modification of LIG. After a stability experiment was conducted at room temperature for four months, no impurity peaks were found by HPLC-DAD analysis, which indicated that LIGc resolved the stability issues of LIG. LIGc was absorbed and eliminated rapidly after intravenous administration (C-max = 6.42 +/- 1.65 mg/L at a dose of 20 mg/kg) and oral administration (T-max = 0.5 h, C-max = 9.89 +/- 1.62 mg/L at a dose of 90 mg/kg, t(1/2z) approximately 2.5 h). The absolute oral bioavailability (F) of LIGc was clearly higher than the F of LIG reported in the literature (F, 83.97 % versus 2.6 %). Linear dose-dependent pharmacokinetics were observed after oral administration, with a higher area under the curve (AUC(0-t), 22.31 +/- 2.88 mg/L*11) observed at 90 mg/kg than that at 45 mg/kg (AUC(0-t), 13.673 +/- 0.666 mall). Tissue distribution results indicated that LIGc easily crossed the blood-brain barrier (BBB) and was distributed widely to the main tissues and organs of rats. We also conducted a preliminary safety assessment of LIGc by means of an acute toxicity test in KM mice. All mice had excellent health status (ig, dosage of 5.0 g/kg), with no histopathological changes observed in the main organs. (C) 2020 Elsevier B.V. All rights reserved.

Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives

Structural Modification of Ligustrazine

Recent Advances in the Structural Modification of Ligustrazine and Cerebro/Cardiovascular Activity of Ligustrazine Derivatives

Research Progress on Pharmacological Effects of Ligustrazine - Ferulic Acid Derivatives

ChemInform Abstract: Ligustrazine Derivatives. Part 5. Design, Synthesis and Biological Evaluation of Novel Ligustrazinyloxy‐Cinnamic Acid Derivatives as Potent Cardiovascular Agents.

Research Progress on Pharmacological Effect of Ligustrazine

Design, Synthesis, and Biological Activities of Novel Ligustrazine Derivatives.

Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents.

Z-ligustilide: A review of its pharmacokinetics and pharmacology

Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides As Cardiovascular Agents

Ligustrazine Derivatives. Part 4: Design, Synthesis, and Biological Evaluation of Novel Ligustrazine-Based Stilbene Derivatives As Potential Cardiovascular Agents

Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.

Synthesis and Biological Evaluation of New Ligustrazine Derivatives As Anti-Tumor Agents

Synthesis Of Ligustrazine-Aromatic Acid Derivatives And Their Inhibitory Effect On Platelet Aggregation

ResearchonPharmacologicalActionofActiveIngredientsofLigusticumWallichiiBasedonBibliometrics

The Preparation of Novel Ligustrazine Derivatives As Potential Cerebrocardiac Vascular Agents.

Pharmacokinetics, tissue distribution, and safety evaluation of a ligustilide derivative (LIGc)

Ligustrazine Monomer Against Cerebral Ischemia/ Reperfusion Injury

Advances in Studies on Pharmacological Functions of Ligustilide and their Mechanisms

Synthesis of Novel Ligustrazine Derivatives As Potential Platelet Aggregation Inhibitors